SynAct Pharma AB Asset Resilience Ratio

Latest as of December 2022: 0.13%

SynAct Pharma AB asset resilience ratio. SynAct Pharma AB (SYNACT) has an Asset Resilience Ratio of 0.13% as of December 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See SYNACT defensive interval ratio to measure how many days the company can operate on defensive assets alone.

Liquid Assets

Skr180.00K

≈ $19.37K USD Cash + Short-term Investments

Total Assets

Skr142.60 Million

≈ $15.35 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio of SynAct Pharma AB (2020–2023)

Asset resilience ratio of SynAct Pharma AB from 2020 to 2023. This chart shows how SynAct Pharma AB's Asset Resilience Ratio has changed over time. Read SynAct Pharma AB (SYNACT) financial obligations for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down SynAct Pharma AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of SynAct Pharma AB.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Skr0.00	0%
Short-term Investments	Skr180.00K	0.13%
Total Liquid Assets	Skr180.00K	0.13%

Asset Resilience Insights

Limited Liquidity: SynAct Pharma AB maintains only 0.13% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

SynAct Pharma AB Industry Peers by Asset Resilience Ratio

Compare SynAct Pharma AB's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Hyloris Developmentsen Sa BR:HYL	Biotechnology	1.36%
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Oruka Therapeutics, Inc. NASDAQ:ORKA	Biotechnology	53.11%
Gempharmatech Co. Ltd. A SHG:688046	Biotechnology	23.95%
Vor Biopharma Inc NASDAQ:VOR	Biotechnology	74.48%
Inventiva S.A PA:IVA	Biotechnology	52.73%
Sunmax Biotechnology Co Ltd TWO:4728	Biotechnology	10.53%
Guangdong VTR Bio-Tech Co Ltd SHE:300381	Biotechnology	4.98%

SynAct Pharma AB Asset Resilience Ratio by Year (2020–2023)

SynAct Pharma AB asset resilience ratio by year from 2020 to 2023. The table below shows the annual Asset Resilience Ratio data for SynAct Pharma AB.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2023-12-31	0.04%	Skr93.00K ≈ $10.01K	Skr228.02 Million ≈ $24.54 Million	-0.09pp
2022-12-31	0.13%	Skr180.00K ≈ $19.37K	Skr142.60 Million ≈ $15.35 Million	+1.09pp
2020-12-31	-0.96%	Skr-208.00K ≈ $-22.38K	Skr21.59 Million ≈ $2.32 Million	--

pp = percentage points

About SynAct Pharma AB

ST:SYNACT Sweden Biotechnology

Market Cap

$94.61 Million

Skr879.17 Million SEK

Market Cap Rank

#19205 Global

#335 in Sweden

Share Price

Skr15.70

Change (1 day)

-2.73%

52-Week Range

Skr10.66 - Skr24.20

All Time High

Skr143.40